One-Shot gene injection aims to halt blinding eye disease
NCT ID NCT06765980
Summary
This early-stage study is testing a new, one-time gene therapy called VV-14295 for people with geographic atrophy (GA), an advanced form of age-related macular degeneration that causes progressive vision loss. Researchers will inject the therapy into the eye to see if it is safe and if it can slow down the growth of the damaging GA lesions. The study will enroll about 62 adults to find the right dose and gather initial evidence on whether the treatment helps preserve vision.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Kriya Clinical Study Site
RECRUITINGOttawa, Ontario, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Kriya Clinical Study Site
RECRUITINGChristchurch, New Zealand
Conditions
Explore the condition pages connected to this study.